John R. Soglia

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

21h-index2.7kcitations31works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(13), Drug-Induced Hepatotoxicity and Protection(5), Metabolomics and Mass Spectrometry Studies(4), Computational Drug Discovery Methods(3), Lung Cancer Treatments and Mutations(3)

Publications31 total

Abstract B154: Safety and preliminary activity of the selective ALK inhibitor NVL-655 in patients with ALK fusion-positive solid tumors
Molecular Cancer Therapeutics·2023· 4 cited
Phase 1 study to evaluate safety, tolerability and pharmacokinetics of a novel intra-tympanic administered thiosulfate to prevent cisplatin-induced hearing loss in cancer patients
Investigational New Drugs·2020· 24 citedOpen Access
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Nature·2016· 845 cited
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate
ACS Medicinal Chemistry Letters·2016· 146 citedOpen Access
Abstract 554: Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models
Cancer Research·2016· 5 cited
Abstract B029: The potent and selective phosphoinositide-3-kinase-gamma inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment
Cancer Immunology Research·2016
Abstract A192: The potent and selective phosphoinositide-3-kinase-γ inhibitor, IPI-549, inhibits tumor growth in murine syngeneic solid tumor models through alterations in the immune suppressive microenvironment
Molecular Cancer Therapeutics·2015
The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway
Xenobiotica·2013· 4 cited
CCDC 771675: Experimental Crystal Structure Determination
The Cambridge Structural Database·2011Open Access
Discovery Tactics To Mitigate Toxicity Risks Due to Reactive Metabolite Formation with 2-(2-Hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one Derivatives, Potent Calcium-Sensing Receptor Antagonists and Clinical Candidate(s) for the Treatment of Osteoporosis
Chemical Research in Toxicology·2010· 25 cited
Evaluation of the metabolism of propranolol by linear ion trap technology in mouse, rat, dog, monkey, and human cryopreserved hepatocytes
Rapid Communications in Mass Spectrometry·2009· 18 cited
High Throughput ADME Screening: Practical Considerations, Impact on the Portfolio and Enabler of In Silico ADME Models
Current Drug Metabolism·2008· 84 cited
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formation
Bioorganic & Medicinal Chemistry Letters·2008· 51 citedOpen Access
Can In Vitro Metabolism-Dependent Covalent Binding Data in Liver Microsomes Distinguish Hepatotoxic from Nonhepatotoxic Drugs? An Analysis of 18 Drugs with Consideration of Intrinsic Clearance and Daily Dose
Chemical Research in Toxicology·2008· 212 cited
A Rational Chemical Intervention Strategy To Circumvent Bioactivation Liabilities Associated with a Nonpeptidyl Thrombopoietin Receptor Agonist Containing a 2-Amino-4-arylthiazole Motif
Chemical Research in Toxicology·2007· 51 cited
NADPH-Dependent Covalent Binding of [<sup>3</sup>H]Paroxetine to Human Liver Microsomes and S-9 Fractions: Identification of an Electrophilic Quinone Metabolite of Paroxetine
Chemical Research in Toxicology·2007· 81 cited
Discovery of<i>N</i>-[(3<i>R</i>)-1-Azabicyclo[2.2.2]oct-3-yl]furo[2,3-<i>c</i>]pyridine-5-carboxamide, an Agonist of the α7 Nicotinic Acetylcholine Receptor, for the Potential Treatment of Cognitive Deficits in Schizophrenia:  Synthesis and Structure−Activity Relationship
Journal of Medicinal Chemistry·2006· 188 citedOpen Access
A Semiquantitative Method for the Determination of Reactive Metabolite Conjugate Levels in Vitro Utilizing Liquid Chromatography−Tandem Mass Spectrometry and Novel Quaternary Ammonium Glutathione Analogues
Chemical Research in Toxicology·2006· 96 cited
A 96-Well Efflux Assay To Identify ABCG2 Substrates Using a Stably Transfected MDCK II Cell Line
Molecular Pharmaceutics·2006· 49 cited
Application of a linear ion trap/orbitrap mass spectrometer in metabolite characterization studies: Examination of the human liver microsomal metabolism of the non-tricyclic anti-depressant nefazodone using data-dependent accurate mass measurements
Journal of the American Society for Mass Spectrometry·2006· 116 cited
page 1 of 2Next →

Frequent Co-authors

Amit S. Kalgutkar(13), Sabrina X. Zhao(13), Vito J. Palombella(6), Melissa Pink(5), Jennifer Proctor(5), Karen McGovern(5), Cornelis E. C. A. Hop(5), Matthew Rausch(4), David A. Winkler(4), Jeremy H. Tchaicha(4), Sujata Sharma(4), Nicole Kosmider(4), Jeffery L. Kutok(4), Somarajan Nair(4), Martin Tremblay(4), Alfredo Castro(4), Mark J. Cole(4), Kerry White(3), Daniel P. Walker(3), Mary E. Lame(3)